Formosa Pharmaceuticals EBIT

The latest EBIT for 6838.TW is $-160M as of March 2026. That compares with $-220M in the prior-year period — up 26.7% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Formosa Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6838.TW's EBIT moved from $-220M to $-160M — a 26.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Formosa Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, 6838.TW currently prints $-160M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Formosa Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-160M for 6838.TW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting 6838.TW's EBIT ($-160M), review year-over-year change from $-220M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.